What is the half-life of Retatrutide?
Retatrutide has a reported half life of ~6 days, given subcutaneous. That is why it is typically dosed once weekly. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~6 days
- Route: Subcutaneous
- Typical schedule: Once weekly
- Cycle length: Open-ended, titrate over 4-6 months
References
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — Jastreboff AM et al., NEJM, 2023
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Rosenstock et al., Lancet, 2023
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Sanyal et al., Nature Medicine, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Retatrutide
Last updated 2026-06-06.